CN116997572A - 小细胞肺癌的分类与治疗的方法和系统 - Google Patents

小细胞肺癌的分类与治疗的方法和系统 Download PDF

Info

Publication number
CN116997572A
CN116997572A CN202180088545.0A CN202180088545A CN116997572A CN 116997572 A CN116997572 A CN 116997572A CN 202180088545 A CN202180088545 A CN 202180088545A CN 116997572 A CN116997572 A CN 116997572A
Authority
CN
China
Prior art keywords
sclc
subject
targeting agent
proteins
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180088545.0A
Other languages
English (en)
Chinese (zh)
Inventor
伊丽莎白·M·帕克
劳伦·A·拜尔斯
卡尔·M·盖伊
约翰·V·海马赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CN116997572A publication Critical patent/CN116997572A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180088545.0A 2020-11-06 2021-11-05 小细胞肺癌的分类与治疗的方法和系统 Pending CN116997572A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063110664P 2020-11-06 2020-11-06
US63/110,664 2020-11-06
PCT/US2021/058218 WO2022098979A1 (en) 2020-11-06 2021-11-05 Methods and systems for classification and treatment of small cell lung cancer

Publications (1)

Publication Number Publication Date
CN116997572A true CN116997572A (zh) 2023-11-03

Family

ID=81457377

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180088545.0A Pending CN116997572A (zh) 2020-11-06 2021-11-05 小细胞肺癌的分类与治疗的方法和系统

Country Status (8)

Country Link
US (1) US20230405117A1 (https=)
EP (1) EP4240755A4 (https=)
JP (1) JP2023548590A (https=)
KR (1) KR20230104233A (https=)
CN (1) CN116997572A (https=)
AU (1) AU2021372988A1 (https=)
CA (1) CA3200665A1 (https=)
WO (1) WO2022098979A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4577578A1 (en) 2022-08-22 2025-07-02 Abdera Therapeutics Inc. Dll3 binding molecules and uses thereof
CN116466089B (zh) * 2023-04-27 2025-10-31 杭州华得森生物技术有限公司 采用微流控芯片与多重免疫荧光探针技术的基于sclc分子分型的ctc的检测试剂盒及其鉴定方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5117765B2 (ja) * 2007-05-28 2013-01-16 国立大学法人 東京大学 抗ｒｏｂｏ１抗体を含むｐｅｔ用腫瘍診断剤
DK2530091T3 (en) * 2010-01-29 2018-05-28 Chugai Pharmaceutical Co Ltd ANTI-DLL3 ANTIBODY
BR112014020826A8 (pt) * 2012-02-24 2017-09-19 Stem Centrx Inc Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco – anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
MA41613A (fr) * 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白

Also Published As

Publication number Publication date
EP4240755A4 (en) 2024-12-18
JP2023548590A (ja) 2023-11-17
AU2021372988A1 (en) 2023-06-22
US20230405117A1 (en) 2023-12-21
CA3200665A1 (en) 2022-05-12
KR20230104233A (ko) 2023-07-07
WO2022098979A1 (en) 2022-05-12
EP4240755A1 (en) 2023-09-13

Similar Documents

Publication Publication Date Title
TWI890283B (zh) 結合ccr8之抗體及融合蛋白及其用途
US20240052354A1 (en) Compositions and methods to treat cancer
KR102775647B1 (ko) 종양을 치료하는 방법
CN111971306A (zh) 治疗肿瘤的方法
US20210380693A1 (en) Methods of treating tumor
US20240384350A1 (en) Methods of treating cancer with kinase inhibitors
CN116997572A (zh) 小细胞肺癌的分类与治疗的方法和系统
EP4301879A1 (en) Methods and systems for diagnosis, classification, and treatment of small cell lung cancer and other high-grade neuroendocrine carcinomas
CN117460843A (zh) 用激酶抑制剂治疗癌症的方法
CN115362005A (zh) 使用波齐替尼治疗具有nrg1融合的癌症
JP2023513006A (ja) Ｎｒｇ１融合体を有するがんの治療のためのｅｇｆｒ／ｈｅｒ２チロシンキナーゼインヒビターおよび／またはｈｅｒ２／ｈｅｒ３抗体の使用
US20240108623A1 (en) Methods of treating cancer with poziotinib
US20250049848A1 (en) Methods and compositions for altering a tumor microbiome
HK40055955A (en) Diagnostic and therapeutic methods for cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination